Co-expressing NPY and its inhibitory receptor Y2 in excitatory hippocampal cells allows inhibitory autoregulation of ...

Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO Oxford, UK – 18 ...

This enhancement introduces a new lentiviral vector manufacturing (LVV ... LVVs are becoming increasingly prominent in the advanced therapy space. Gene transfer using LVVs has been applied to treat ...

Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm’s clinical program is a LVV-based gene therapy for ...

SkyQuest projects that the Global Gene Therapy Market will reach a value of USD 38.34 Billion by 2031, with a CAGR of 19% during the forecast period (2024-2031).Numerous factors are responsible for ...

Gene therapy for SCID-X1 ... leukemogenesis with further genetic abnormalities. gretroviral and lentiviral vectors with a vector-specific nonrandom integration pattern in target cell genomes ...

Milan, Italy, 12 September 2024 – Genespire, a biotechnology company developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases, today announces the appointment of ...

Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), announced today that it has entered into a multi-target antibody discovery collaboration with ...

Researchers tested a preclinical model for an experimental gene therapy designed to treat multiple sulfatase deficiency (MSD), a disorder that affects the brain, lungs, skin, and skeleton with no ...